S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
OTCMKTS:NEVPF

Abliva AB (publ) News Headlines

$0.07
0.00 (-4.29 %)
(As of 10/22/2021 10:58 AM ET)
Add
Compare
Today's Range
$0.07
$0.07
50-Day Range
$0.06
$0.15
52-Week Range
$0.06
$0.15
Volume5,100 shs
Average Volume5,653 shs
Market Capitalization$18.07 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Media Mentions By Week

Abliva AB (publ) Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NEVPF
News Sentiment

0.98

0.37

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NEVPF Articles
This Week

0

0

NEVPF Articles
Average Week

Get Abliva AB (publ) News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEVPF and its competitors with MarketBeat's FREE daily newsletter.

Abliva AB (publ) (OTCMKTS NEVPF) News Headlines Today

SourceHeadline
MarketBeat logoAbliva AB (publ) (OTCMKTS:NEVPF) Short Interest Update
americanbankingnews.com - October 17 at 1:57 PM
MarketBeat logoAbliva AB (publ) (OTCMKTS:NEVPF) Stock Price Up 37.5%
americanbankingnews.com - October 14 at 12:28 AM
finanznachrichten.de logoBioInvent strengthens Investor Relations
finanznachrichten.de - November 28 at 9:20 PM
finance.yahoo.com logoVenture Fund Manager Has $100 Million for Startups Run by Women
finance.yahoo.com - June 28 at 1:38 PM
finance.yahoo.com logoHere's Why NeuroVive Pharmaceutical (STO:NVP) Must Use Its Cash Wisely
finance.yahoo.com - April 7 at 3:44 AM
seekingalpha.com logoNeuroVive Pharmaceutical AB reports Q4 results
seekingalpha.com - February 19 at 5:55 AM
finance.yahoo.com logoInvestors Who Bought NeuroVive Pharmaceutical (STO:NVP) Shares Five Years Ago Are Now Down 98%
finance.yahoo.com - February 4 at 9:33 AM
markets.businessinsider.com logoNeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
markets.businessinsider.com - December 20 at 2:12 PM
seekingalpha.com logoNeuroVive settles dispute with CicloMulsion AG
seekingalpha.com - December 16 at 9:49 AM
finance.yahoo.com logoNeuroVive Announces Settlement in Dispute With CicloMulsion AG
finance.yahoo.com - December 16 at 9:49 AM
ca.finance.yahoo.com logoHow Much Did NeuroVive Pharmaceutical AB's (STO:NVP) CEO Pocket Last Year?
ca.finance.yahoo.com - December 4 at 7:52 AM
finance.yahoo.com logoHow Much Did NeuroVive Pharmaceutical AB's (STO:NVP) CEO Pocket Last Year?
finance.yahoo.com - December 4 at 7:52 AM
finance.yahoo.com logoHave Insiders Been Buying NeuroVive Pharmaceutical AB (STO:NVP) Shares?
finance.yahoo.com - October 29 at 8:27 AM
finance.yahoo.com logoWe Think NeuroVive Pharmaceutical (STO:NVP) Needs To Drive Business Growth Carefully
finance.yahoo.com - September 26 at 2:42 PM
finance.yahoo.com logoHow Does Investing In NeuroVive Pharmaceutical AB (STO:NVP) Impact The Volatility Of Your Portfolio?
finance.yahoo.com - August 23 at 4:17 PM
finance.yahoo.com logoCatalyst Pharma (CPRX) Rides on Successful Launch of Firdapse
finance.yahoo.com - May 22 at 4:28 PM
finance.yahoo.com logoNeuroVive Pharmaceutical AB Interim Report January - March 2019
finance.yahoo.com - May 21 at 12:27 PM
finance.yahoo.com logoNeuroVive Pharmaceutical AB Publishes 2018 Annual Report
finance.yahoo.com - March 25 at 11:30 AM
finance.yahoo.com logoNeuroVive Receives SEK 28.2 Million in a Directed New Share Issue
finance.yahoo.com - March 7 at 12:16 PM
finance.yahoo.com logoNeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research Compounds
finance.yahoo.com - February 21 at 1:01 PM
Get Abliva AB (publ) News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEVPF and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.